Overview
MRK market data
Price History
MRK price chart
Valuation & Profitability
- P/E (TTM)
- 34.91 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $7.28 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.21 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 275.1% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $76.66 – $130.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $311.9K · P/B 4.97 · P/S 4.74.
Company news
Merck Announces Strategy For Rapid, Broad And Sustainable Access To Its HIV-1 Prevention Pill Alimatravir In Low- And Middle-Income CountriesBenzinga · Jul 24, 2026, 10:49 AM
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative ColitisBenzinga · Jul 23, 2026, 6:06 PM
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?The Motley Fool · Jul 22, 2026, 9:15 PM
Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.The Motley Fool · Jul 22, 2026, 4:30 PM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Gilead, Merck Advance Potential Blockbuster Weekly HIV PillBenzinga · Jul 21, 2026, 5:28 PM
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your PortfolioBenzinga · Jul 20, 2026, 9:11 PM
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?Benzinga · Jul 20, 2026, 6:45 PM